Skip to content
lifestyle.d-h.st
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
June 30, 2026
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
June 14, 2026
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
June 14, 2026
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
May 22, 2026
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
April 27, 2026
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
April 8, 2026
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
February 11, 2026